We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Major Development Could Further Advance Personalized Cancer Therapy

By LabMedica International staff writers
Posted on 19 Jan 2010
Scientists are gaining ground on exploiting new technologies to customize an individual's cancer therapy based on their genetic makeup. More...


Researchers from Georgetown Lombardi Comprehensive Cancer Center (Washington DC, USA) reported a significant advance in this field of research using a new chip that hunts for hundreds of mutations in dozen of genes.

The goal of personalized medicine is to determine the best treatment and the optimal dose carrying the fewest side effects, particularly as new drugs are discovered and treatment options increase. Variations in an individual's genes encode proteins, which affect how a drug is metabolized or taken in by the cells. This directly influences the drug's effectiveness and the kinds of side effects that may be caused by its toxicity.

"Currently, available genotyping tools test only a few genes at a time,” explained Dr. John F. Deeken, a pharmacogentic researcher at Lombardi. "With a new chip called DMET, as many as 170 genes can be examined for more than a thousand variations. This type of turnkey testing, if validated, could eventually replace highly specialized, time-consuming, and labor-intensive testing--thus allowing more institutes the opportunity to pursue genotyping and pharmocogenetic research. That alone would be a significant development for our field and for expediting the research many of us believe is the future of medicine.”

Such a development is especially critical for cancer research, both in terms of drug discovery and treatment. Genetic variability among patients in cancer clinical trials is not typically taken into account, a factor that could skew dosage amounts and doom an otherwise promising new drug. A simpler and faster test could be readily integrated into treatment trials.

In his article published online December 29, 2009, in The Pharmacogenomics Journal, Dr. Deeken and colleagues reported results of the new genotyping platform called DMET (drug-metabolizing enzymes and transporters), developed by Affymetrix, Inc. (Santa Clara, CA, USA). The DMET "casts a wider net,” screening for 1256 genetic variations in 170 genes involved in drug absorption, distribution, metabolism, and excretion.

According to Dr. Deeken, one of the main obstacles facing pharmocogenetic researchers is the lack of a proven and relatively quick technology for genotyping. "DMET appears to offer great promise in this field as a reliable test unveiling genetic variations that correlated with drug effectiveness and toxicity,” stated Dr. Deeken. "Still, DMET isn't yet ready for primetime in terms of having received FDA [U.S. Food and Drug Administration] approval, but we're getting closer.”

Dr. Deeken serves as a consultant to Sanofi-Aventis (Bridgewater, NJ, USA), the manufacturer of docetaxel, a drug involved in the study.

Related Links:

Georgetown Lombardi Comprehensive Cancer Center
Affymetrix



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.